Lymphoma Clinical Trials

Showing 2701-2720 of 3,379 trials

CNS Prophylaxis in Diffuse Large B-cell Lymphoma

NCT02777736

Comparison of cumulative incidence of CNS relapses in patients with diffuse large B-cell lymphoma with intermediate or high risk of CNS relapse treated with CNS prophylaxis: either with 2 doses of intravenous methotrexate 3g/m2 i.v.(arm A) or 6 doses of intrathecal methotrexate 12mg (arm B) and in patients with low risk of CNS relapse without CNS prophylaxis (arm C).

Diffuse Large B-cell Lymphoma

Czech Lymphoma Study Group500 participantsStarted Jul 2015

Brno, Czechia • Hradec Králové, Czechia • Ostrava, Czechia +3 more locations

COMPLETEDPhase 1

VEGF Trap in Treating Patients With Solid Tumors or Non-Hodgkin's Lymphoma

NCT00045266

RATIONALE: VEGF Trap may stop the growth of solid tumors or non-Hodgkin's lymphoma by stopping blood flow to the cancer. PURPOSE: Phase I trial to study the effectiveness of VEGF Trap in treating patients who have relapsed or refractory solid tumors or non-Hodgkin's lymphoma.

LymphomaUnspecified Adult Solid Tumor, Protocol Specific

Regeneron PharmaceuticalsStarted Apr 2002

New York, New York, United States

COMPLETEDPhase 2

Monoclonal Antibody CT-011 in Combination With Rituximab in Patients With Relapsed Follicular Lymphoma

NCT00904722

The goal of this clinical research study is to learn if the combination of the immunotherapy drugs, CT-011 and rituximab, can help control follicular lymphoma. The safety of this drug combination will also be studied.

Lymphoma

M.D. Anderson Cancer Center32 participantsStarted Jan 2010

Houston, Texas, United States

CNS Prophylaxis in Diffuse Large B-cell Lymphoma

VEGF Trap in Treating Patients With Solid Tumors or Non-Hodgkin's Lymphoma

Monoclonal Antibody CT-011 in Combination With Rituximab in Patients With Relapsed Follicular Lymphoma

Related Searches

A Study to Evaluate the Efficacy and Safety of Ibrutinib, in Patients With Mantle Cell Lymphoma Who Progress After Bortezomib Therapy

A Multicentre, Randomized Phase III Study of Rituximab as Maintenance Treatment Versus Observation in Patients With Aggressive B-cell Lymphoma: NHL-13

Lenalidomide in HTLV-1 Adult T-Cell Leukemia

Imaging Based Dosimetry for Individualized Internal Emitter Therapy

Study of RAD001 in Patients With Relapsed/Refractory Hodgkin Lymphoma That Has Progressed After High-dose Chemotherapy and Autologous Stem Cell Transplant and/or After Gemcitabine- or Vinorelbine- or Vinblastine-based Treatment.

A Study Comparing the Efficiency and Safety of S-CHOP(Cyclophosphamide, Hydroxydaunomycin, Oncovin, and Prednisone) Versus R-CHOP in Untreated CD20(Cluster of Differentiation Antigen 20)-Positive DLBCL Patients

Pentostatin, Cyclophosphamide, Rituximab, and Mitoxantrone in Treating Patients With Chronic Lymphocytic Leukemia or Other Low-Grade B-Cell Cancer

Bortezomib and Gemcitabine Hydrochloride in Treating Patients With Relapsed or Refractory Hodgkin's Lymphoma

Study of Carfilzomib in Chronic Lymphocytic Leukemia (CLL), Small Lymphocytic Lymphoma (SLL) or Prolymphocytic Leukemia (PLL)

PERCIST Criteria for Response Evaluation With Solid Tumors

Registry Study of T Cell Depleted Allo Non-Myeloablative Stem Cell Transplant

CyBeR Association in Relapsed/Refractory DLBCL

INHIBITOR: Retrospective Study Of Patients With Renal Cell Carcinoma And Mantle Cell Lymphoma Treated With Temsirolimus

A Study of Obinutuzumab in Chinese Participants With CD20+ Malignant Disease

Thiotepa-based Conditioning for Allogeneic Stem-cell Transplantation (SCT) in Lymphoid Malignancies

Treosulfan-based Conditioning for Allogeneic Stem-cell Transplantation (SCT) in Lymphoid Malignancies

Early Diagnosis of Mycosis Fungoides